Pipeline

Novel Insulin Sensitizers to Treat Type 2 Diabetes
Verva has discovered a novel therapeutic intervention for the treatment of type 2 diabetes.  The clinical exemplar of Verva technology is VVP808 (methazolamide), which was originally approved in North America as a treatment for glaucoma. Verva Preclinical studies have  established that VVP808 enhances insulin action and increases glucose disposal by complete oxidation.  Moreover, VVP808 has more than additive activity in combination with first-line diabetes therapy metformin.  In 2012, Verva successfully completed a randomized, placebo-controlled clinical proof-of-concept study, wherein VVP808 reduced levels of the diabetes marker HbA1c, improved markers of liver function and caused weight loss in patients with type 2 diabetes.  On-going mechanistic studies have discovered that VVP808 has a novel mode-of-action which has not previously been evaluated in diabetes therapy.  Moreover, this mode-of-action may have utility in other unmet medical needs beyond metabolic disorders.

Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
The VVP808 clinical proof-of-concept study demonstrated that VVP808 significantly reduced serum levels of alanine transaminase (ALT), indicating VVP808-mediated improvement in liver function and/or reversal of liver damage.  Remarkably, the ALT reduction occurred within the first 2 weeks of treatment and persisted throughout the 24 week treatment period.  Subsequent preclinical studies found that VVP808 reduced liver lipid levels and reversed hepatic steatosis in diabetic mice.  NAFLD and NASH are significant and growing unmet medical needs and there are currently no approved therapies to treat these conditions.

VVP100X: Next Generation Therapies from  VVP808
Verva has a discovery program to identify potent, proprietary next-generation molecules based on the VVP808 novel therapeutic target and mode-of-action.  A library of VVP100X molecules has been synthesized for target screening.

Prevention and Treatment of Obesity and Related Complications
Verva has generated preclinical proof-of-concept with 2 technologies that act directly in adipose tissue to prevent de novo fat cell formation. Verva Fat Blockers represent a novel approach to obesity therapy with multiple potential indications, including weight and fat loss in obesity; prevent of weight and fat re-gain after diet or surgery; adjuvant therapy to prevent drug-induced weight gain; and prevention and reversal of diabetes.